SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
FRNM

Freenome, Inc. (FRNM)

NASDAQ: FRNM · USD
Healthcare · Diagnostics & Research
$9.36-$0.57 (-5.69%)
 
Market cap
$1.04B
Insider Score
Analyst consensus
Market Cap$1.04B-12.9%
Revenue (ttm)$217.86M
Net Income-$110.75M
EPS-$1.20
Shares Out111.50M
PE Ration/a
Forward PE-3.74
Dividendn/a
Ex-Dividend Daten/a
Volume621,416
Open$9.82
Previous Close$9.93
Day's Range$9.28 - $9.84
52-Week Range$9.28 - $17.50
Beta0.60
AnalystsStrong Buy
Price Target$18.00(+92.31%)
Earnings Daten/a

About FRNM

Freenome, Inc., a biotechnology company, develops blood-based screening tests to detect cancer in the United States. The company offers an early cancer detection platform that integrates multiomics, artificial intelligence, and machine learning to uncover complex biological signals associated with cancer. It develops SimpleScreen™ CRC, a blood-based test, including a test for colorectal cancer screening, as well as tests for multi-cancer and multi-disease detection, such as lung, breast, cervical, liver, pancreatic, and esophageal cancers. The company was founded in 2014 and is headquartered in Brisbane, California.

Address
3300 Marina Boulevard, Brisbane, CA, 94005, United States
Market Cap
1.04 billion
Employees
363
Industrial Classification
Diagnostics & Research
1 Day
-5.69%
5 Days
-10.09%
1 Month
-28.55%
6 Months
-16.20%
1 Year
-12.93%

$FRNM stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in FRNM holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by FRNM's directors and management

Net Shares Purchased by Insiders−1−102025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

FRNM Estimated quarterly lobbying spending

Source: U.S. Senate LDA

FRNM Revenue by Segment or Geography

FRNM's latest filing doesn't break out revenue by segment.

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New FRNM patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to FRNM from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from FRNM’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
No data yet
—
Analyst Ratings
62% of score
99
News & Sentiment
38% of score
72

News check: Q3 2026 results show swing to profitability and rising revenue, offset by participation in analyst conference without major announcements.

Recent Insider Activity

Buys
0
Sells
0
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

ARKGARK Genomic Revolution ETF1.03%
TMEDT. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETF0.73%
TNXTT. Rowe Price Innovation Leaders ETF0.13%
TSEET. Rowe Price Small Cap ETF0.12%

Weight is the stock’s share of each fund’s holdings.